Glucokinase as an emerging anti-diabetes target and recent progress in the development of its agonists
Type 2 diabetes mellitus is a metabolic disorder with complicated pathogenesis, and mono-target therapy often fails to effectively manage the levels of blood glucose. In recent years, the anti-diabetes target glucokinase (GK) has attracted the attention of researchers. It acts as a glucose sensor, t...
Saved in:
Main Authors: | Yixin Ren (Author), Li Li (Author), Li Wan (Author), Yan Huang (Author), Shuang Cao (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2022-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Decreased expression of hepatic glucokinase in type 2 diabetes
by: Rebecca A. Haeusler, et al.
Published: (2015) -
Genetic and clinical characteristics of Chinese children with Glucokinase-maturity-onset diabetes of the young (GCK-MODY)
by: Xiuzhen Li, et al.
Published: (2018) -
Effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual‐acting glucokinase activator
by: Jia Miao, et al.
Published: (2022) -
Impaired β-cell glucokinase as an underlying mechanism in diet-induced diabetes
by: Brian Lu, et al.
Published: (2018) -
Mu Opioid Receptor Heterodimers Emerge as Novel Therapeutic Targets: Recent Progress and Future Perspective
by: Li Zhang, et al.
Published: (2020)